SLFN11的甲基化是结直肠癌预后不良和顺铂耐药的一个标志物。
Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer.
作者信息
He Tao, Zhang Meiying, Zheng Ruipan, Zheng Shufang, Linghu Enqiang, Herman James G, Guo Mingzhou
机构信息
Department of Gastroenterology & Hepatology, Chinese PLA General Hospital, #28 Fuxing Road, Beijing 100853, China.
Department of Pathology, The Affiliated Hospital of Logistics University of Chinese People's Armed Police Force, Tianjin 300162, China.
出版信息
Epigenomics. 2017 Jun;9(6):849-862. doi: 10.2217/epi-2017-0019. Epub 2017 Apr 13.
AIM
The expression of human SLFN11 was reported to sensitize cancer cells to DNA damaging agents. This study is to explore the epigenetic change and the function of SLFN11 in human colorectal cancer (CRC).
MATERIALS & METHODS: Six CRC cell lines and 128 primary CRC samples were used.
RESULTS
SLFN11 was methylated in 55.47% (71/128) of primary CRC. The expression of SLFN11 was regulated by promoter region methylation. Methylation of SLFN11 was significantly associated with age, poor 5-year overall survival and 5-year relapse-free survival (all p < 0.05). SLFN11 suppressed CRC cell growth both in vitro and in vivo and sensitized CRC cells to cisplatin.
CONCLUSION
SLFN11 is frequently methylated in human CRC, and the expression of SLFN11 is regulated by promoter region methylation. Methylation of SLFN11 reduced the sensitivity of CRC cells to cisplatin.
目的
据报道，人类SLFN11的表达可使癌细胞对DNA损伤剂敏感。本研究旨在探讨SLFN11在人类结直肠癌（CRC）中的表观遗传变化及其功能。
材料与方法
使用了6种CRC细胞系和128例原发性CRC样本。
结果
55.47%（71/128）的原发性CRC中SLFN11发生甲基化。SLFN11的表达受启动子区域甲基化调控。SLFN11甲基化与年龄、5年总生存率和5年无复发生存率显著相关（均p<0.05）。SLFN11在体外和体内均抑制CRC细胞生长，并使CRC细胞对顺铂敏感。
结论
SLFN11在人类CRC中经常发生甲基化，其表达受启动子区域甲基化调控。SLFN11甲基化降低了CRC细胞对顺铂的敏感性。
Zotero 插件